On the heels of yet another FCPA settlement announced just this week by a global medical device manufacturer to resolve claims that company officials made illegal payments to public health officials in Greece, one fact is clear – the life sciences "industry sweep" is in full swing…and this is only the beginning…
Don’t miss this rare opportunity to gain firsthand knowledge from senior counsel directly involved in recent high profile FCPA settlements within the life sciences industry.
Take note during the opening panel of the conference, The Sweep in Review: Where We Are, What We’ve Learned and What’s Next, as the session leaders provide practical guidance on how enhanced compliance obligations outlined in Attachment D of the 2011 Johnson & Johnson deferred prosecution agreement, as well as other recent settlement agreements, can be incorporated into your global anti-corruption compliance program across key areas including:
Gifts, entertainment and hospitality
Internal reporting systems
Risk assessments and audits
M&As and collaborations
Third parties, particularly agents, sales reps, consultants and other HCPs
Benchmark and network with your in-house colleagues from: Baxter, Biomet, Carestream Health, C.R. Bard, Elan Pharmaecuticals, Eli Lilly, General Electric, GE Healthcare, Johnson & Johnson, Lundbeck, Medtronic, Novartis Pharma, Pfizer, Sandoz, Takeda Pharmaceuticals, Wright Medical.
Also new for this year, hear from the IRS as a representative from IRS Criminal Investigations provides a Behind-the-Scenes Look into IRS’ Role in FCPA Enforcement
Ensure your team is equipped with the tools it needs to withstand an FCPA investigation in this era of heightened enforcement. Learn what to do now to minimize your company’s FCPA exposure tomorrow.